Orthofix Medical (OFIX) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales reached $196.6 million, up 7% year-over-year, with strong growth in U.S. Spine Fixation, Bone Growth Therapies, and U.S. Orthopedics, which delivered a record quarter with 15% growth.

• Adjusted EBITDA rose to $19.2 million, a $5.7 million increase year-over-year, with margin expansion of approximately 250 basis points and positive free cash flow of $5.9 million.

• Announced a new $275 million credit facility to optimize capital structure, lower cost of capital, and support long-term growth.

• New three-year financial targets unveiled, aiming for 6%–7% net sales CAGR, mid-teens adjusted EBITDA margin by 2027, and sustained positive free cash flow.

• Leadership transition completed, with a new management team focused on disciplined, profitable growth and innovation.

Financial highlights

• Q3 2024 net sales: $196.6 million (+7% YoY); U.S. Spine Fixation up 18%, Bone Growth Therapies up 9%, U.S. Orthopedics up 15%.

• Adjusted EBITDA was $19.2 million, with margin expansion to 9.8% (up from 7.3% in Q3 2023); gross margin reached 71.3% (non-GAAP).

• Net loss for Q3 2024 was $27.4 million, or $(0.71) per share, an improvement from Q3 2023.

• Free cash flow for Q3 2024 was $5.9 million, a significant turnaround from prior quarters.

• Cash, cash equivalents, and restricted cash totaled $32.6 million at September 30, 2024.

Outlook and guidance

• Reiterated full-year 2024 net sales guidance of $795–$800 million (6.6%–7.2% YoY growth) and adjusted EBITDA of $64–$69 million, with expectations to remain free cash flow positive.

• New three-year targets (2025–2027): 6%–7% net sales CAGR, mid-teens adjusted EBITDA margin by 2027, and continued positive free cash flow.

• Assumptions include 4%–5% weighted average market growth, 300 bps gross margin expansion, and continued synergy capture.

• Management expects continued growth in U.S. Spine and Orthopedics, supported by expanded distribution and new product launches.